 | • レポートコード：MRC2-11QY12072 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は移植片対宿主病（GVHD）治療のグローバル市場について調査・分析したレポートです。種類別（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト）市場規模、用途別（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別移植片対宿主病（GVHD）治療の競争状況、市場シェア ・世界の移植片対宿主病（GVHD）治療市場：種類別市場規模 2015年-2020年（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト） ・世界の移植片対宿主病（GVHD）治療市場：種類別市場規模予測 2021年-2026年（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト） ・世界の移植片対宿主病（GVHD）治療市場：用途別市場規模 2015年-2020年（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD）） ・世界の移植片対宿主病（GVHD）治療市場：用途別市場規模予測 2021年-2026年（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD）） ・北米の移植片対宿主病（GVHD）治療市場分析：米国、カナダ ・ヨーロッパの移植片対宿主病（GVHD）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの移植片対宿主病（GVHD）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の移植片対宿主病（GVHD）治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの移植片対宿主病（GVHD）治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol-Myers Squibb、Abbott、AbbVie、Allergan、Anterogen、Astellas Pharma、Athersys、Caladrius、Eli Lilly、GlaxoSmithKline、Glenmark、Kadmon Holdings、Osiris Therapeutics、Sanofi、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.
Market Analysis and Insights: Global Graft Versus Host Disease (GVHD) Treatment Market
The global Graft Versus Host Disease (GVHD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Graft Versus Host Disease (GVHD) Treatment Scope and Market Size
Graft Versus Host Disease (GVHD) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease (GVHD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
GlaxoSmithKline
Glenmark
Kadmon Holdings
Osiris Therapeutics
Sanofi
Takeda
Market segment by Type, the product can be split into
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept
Market segment by Application, split into
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue
1.4 Market by Type
1.4.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Monoclonal Antibodies
1.4.3 MTOR Inhibitors
1.4.4 Tyrosine Kinase Inhibitors
1.4.5 Thalidomide
1.4.6 Etanercept
1.5 Market by Application
1.5.1 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Acute Graft Versus Host Disease (aGvHD)
1.5.3 Chronic Graft Versus Host Disease (cGvHD)
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Perspective (2015-2026)
2.2 Global Graft Versus Host Disease (GVHD) Treatment Growth Trends by Regions
2.2.1 Graft Versus Host Disease (GVHD) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Graft Versus Host Disease (GVHD) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Graft Versus Host Disease (GVHD) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Graft Versus Host Disease (GVHD) Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Market Size
3.1.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue (2015-2020)
3.1.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio
3.2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease (GVHD) Treatment Revenue in 2019
3.3 Graft Versus Host Disease (GVHD) Treatment Key Players Head office and Area Served
3.4 Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
3.5 Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
5.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
6.2 Graft Versus Host Disease (GVHD) Treatment Key Players in North America (2019-2020)
6.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
6.4 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
7.2 Graft Versus Host Disease (GVHD) Treatment Key Players in Europe (2019-2020)
7.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
7.4 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
8 China
8.1 China Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
8.2 Graft Versus Host Disease (GVHD) Treatment Key Players in China (2019-2020)
8.3 China Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
8.4 China Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
9.2 Graft Versus Host Disease (GVHD) Treatment Key Players in Japan (2019-2020)
9.3 Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
9.4 Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
10.2 Graft Versus Host Disease (GVHD) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
11 India
11.1 India Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
11.2 Graft Versus Host Disease (GVHD) Treatment Key Players in India (2019-2020)
11.3 India Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
11.4 India Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2020)
12.2 Graft Versus Host Disease (GVHD) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Details
13.1.2 Bristol-Myers Squibb Business Overview
13.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Introduction
13.1.4 Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020))
13.1.5 Bristol-Myers Squibb Recent Development
13.2 Abbott
13.2.1 Abbott Company Details
13.2.2 Abbott Business Overview
13.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Introduction
13.2.4 Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.2.5 Abbott Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Introduction
13.3.4 AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Allergan
13.4.1 Allergan Company Details
13.4.2 Allergan Business Overview
13.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Introduction
13.4.4 Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.4.5 Allergan Recent Development
13.5 Anterogen
13.5.1 Anterogen Company Details
13.5.2 Anterogen Business Overview
13.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Introduction
13.5.4 Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.5.5 Anterogen Recent Development
13.6 Astellas Pharma
13.6.1 Astellas Pharma Company Details
13.6.2 Astellas Pharma Business Overview
13.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Introduction
13.6.4 Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.6.5 Astellas Pharma Recent Development
13.7 Athersys
13.7.1 Athersys Company Details
13.7.2 Athersys Business Overview
13.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Introduction
13.7.4 Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.7.5 Athersys Recent Development
13.8 Caladrius
13.8.1 Caladrius Company Details
13.8.2 Caladrius Business Overview
13.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Introduction
13.8.4 Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.8.5 Caladrius Recent Development
13.9 Eli Lilly
13.9.1 Eli Lilly Company Details
13.9.2 Eli Lilly Business Overview
13.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Introduction
13.9.4 Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.9.5 Eli Lilly Recent Development
13.10 GlaxoSmithKline
13.10.1 GlaxoSmithKline Company Details
13.10.2 GlaxoSmithKline Business Overview
13.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Introduction
13.10.4 GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
13.10.5 GlaxoSmithKline Recent Development
13.11 Glenmark
10.11.1 Glenmark Company Details
10.11.2 Glenmark Business Overview
10.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Introduction
10.11.4 Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
10.11.5 Glenmark Recent Development
13.12 Kadmon Holdings
10.12.1 Kadmon Holdings Company Details
10.12.2 Kadmon Holdings Business Overview
10.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Introduction
10.12.4 Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
10.12.5 Kadmon Holdings Recent Development
13.13 Osiris Therapeutics
10.13.1 Osiris Therapeutics Company Details
10.13.2 Osiris Therapeutics Business Overview
10.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Introduction
10.13.4 Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
10.13.5 Osiris Therapeutics Recent Development
13.14 Sanofi
10.14.1 Sanofi Company Details
10.14.2 Sanofi Business Overview
10.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Introduction
10.14.4 Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
10.14.5 Sanofi Recent Development
13.15 Takeda
10.15.1 Takeda Company Details
10.15.2 Takeda Business Overview
10.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Introduction
10.15.4 Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
10.15.5 Takeda Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Graft Versus Host Disease (GVHD) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue
Table 3. Ranking of Global Top Graft Versus Host Disease (GVHD) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Monoclonal Antibodies
Table 6. Key Players of MTOR Inhibitors
Table 7. Key Players of Tyrosine Kinase Inhibitors
Table 8. Key Players of Thalidomide
Table 9. Key Players of Etanercept
Table 10. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2015-2020)
Table 14. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Graft Versus Host Disease (GVHD) Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Graft Versus Host Disease (GVHD) Treatment Players
Table 21. Global Graft Versus Host Disease (GVHD) Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players (2015-2020)
Table 23. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2019)
Table 24. Global Graft Versus Host Disease (GVHD) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
Table 27. Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Graft Versus Host Disease (GVHD) Treatment Market Size Share by Type (2015-2020)
Table 31. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Graft Versus Host Disease (GVHD) Treatment Market Size Share by Application (2015-2020)
Table 33. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Graft Versus Host Disease (GVHD) Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 37. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 39. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 43. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 45. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 49. China Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 51. China Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 55. Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 57. Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 61. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 67. India Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 69. India Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Graft Versus Host Disease (GVHD) Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Graft Versus Host Disease (GVHD) Treatment Market Share (2019-2020)
Table 73. Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Graft Versus Host Disease (GVHD) Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Graft Versus Host Disease (GVHD) Treatment Market Share by Application (2015-2020)
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Product
Table 80. Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Abbott Company Details
Table 83. Abbott Business Overview
Table 84. Abbott Product
Table 85. Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 86. Abbott Recent Development
Table 87. AbbVie Company Details
Table 88. AbbVie Business Overview
Table 89. AbbVie Product
Table 90. AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 91. AbbVie Recent Development
Table 92. Allergan Company Details
Table 93. Allergan Business Overview
Table 94. Allergan Product
Table 95. Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 96. Allergan Recent Development
Table 97. Anterogen Company Details
Table 98. Anterogen Business Overview
Table 99. Anterogen Product
Table 100. Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 101. Anterogen Recent Development
Table 102. Astellas Pharma Company Details
Table 103. Astellas Pharma Business Overview
Table 104. Astellas Pharma Product
Table 105. Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 106. Astellas Pharma Recent Development
Table 107. Athersys Company Details
Table 108. Athersys Business Overview
Table 109. Athersys Product
Table 110. Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 111. Athersys Recent Development
Table 112. Caladrius Business Overview
Table 113. Caladrius Product
Table 114. Caladrius Company Details
Table 115. Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 116. Caladrius Recent Development
Table 117. Eli Lilly Company Details
Table 118. Eli Lilly Business Overview
Table 119. Eli Lilly Product
Table 120. Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 121. Eli Lilly Recent Development
Table 122. GlaxoSmithKline Company Details
Table 123. GlaxoSmithKline Business Overview
Table 124. GlaxoSmithKline Product
Table 125. GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 126. GlaxoSmithKline Recent Development
Table 127. Glenmark Company Details
Table 128. Glenmark Business Overview
Table 129. Glenmark Product
Table 130. Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 131. Glenmark Recent Development
Table 132. Kadmon Holdings Company Details
Table 133. Kadmon Holdings Business Overview
Table 134. Kadmon Holdings Product
Table 135. Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 136. Kadmon Holdings Recent Development
Table 137. Osiris Therapeutics Company Details
Table 138. Osiris Therapeutics Business Overview
Table 139. Osiris Therapeutics Product
Table 140. Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 141. Osiris Therapeutics Recent Development
Table 142. Sanofi Company Details
Table 143. Sanofi Business Overview
Table 144. Sanofi Product
Table 145. Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 146. Sanofi Recent Development
Table 147. Takeda Company Details
Table 148. Takeda Business Overview
Table 149. Takeda Product
Table 150. Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020) (Million US$)
Table 151. Takeda Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Monoclonal Antibodies Features
Figure 3. MTOR Inhibitors Features
Figure 4. Tyrosine Kinase Inhibitors Features
Figure 5. Thalidomide Features
Figure 6. Etanercept Features
Figure 7. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2020 VS 2026
Figure 8. Acute Graft Versus Host Disease (aGvHD) Case Studies
Figure 9. Chronic Graft Versus Host Disease (cGvHD) Case Studies
Figure 10. Graft Versus Host Disease (GVHD) Treatment Report Years Considered
Figure 11. Global Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players in 2019
Figure 16. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Graft Versus Host Disease (GVHD) Treatment Revenue in 2019
Figure 18. North America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
キャッスルマン病治療の世界市場（～2026年） Castleman disease is a rare condition of lymph nodes and similar tissues. This condition occurs when too many non-cancer cells started to grow in the lymph node. After initial growth hard growth started to form. Usually, it occurs in the chest, abdomen or neck. This condition is also called as angio…- 炎症性腸疾患（IBD）治療の世界市場（～2026年） Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes t…
- クラッベ病治療の世界市場（～2026年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- 感染症治療の世界市場（～2026年） Treatment for Infectious Diseases. Treatment of viral infections such as HIV involves patient care and moral support including antiretroviral therapy. Bacterial infections can be treated by administering antibiotics to the patients. Market Analysis and Insights: Global Infectious Disease Treatment M…
- レイノー病治療の世界市場（～2026年） Market Analysis and Insights: Global Raynauds Disease Treatment Market The global Raynauds Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Raynauds Disease Treatment Scope and Market Size Raynauds Dis…